veliparib + FOLFIRI

Veliparib + FOLFIRI is an investigational combination chemotherapy regimen comprised of **veliparib**, a potent poly(ADP-ribose) polymerase (PARP) inhibitor, and **FOLFIRI**, a standard regimen for advanced or metastatic colorectal and other gastrointestinal cancers consisting of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan[1][2][3][5]. Veliparib enhances the activity of irinotecan by inhibiting DNA repair mechanisms, leading to synergistic cancer cell death, while FOLFIRI disrupts DNA synthesis and replication[5]. This combination has been evaluated primarily in patients with advanced solid tumors, including metastatic colorectal cancer, in phase 1 and phase 2 trials. The regimen is administered intravenously in cycles and is not approved for clinical use outside of research settings. The combination aims to exploit the DNA-damaging actions of FOLFIRI together with veliparib’s inhibition of DNA damage repair, potentially improving efficacy in tumours with enhanced repair pathways[1][3][5].